US 12,180,298 B2
Heavy chain antibodies binding to PSMA
Wim van Schooten, Newark, CA (US); Starlynn Clarke, Newark, CA (US); Kevin Dang, Newark, CA (US); and Ben Buelow, Newark, CA (US)
Assigned to TENEOBIO, INC., Thousand Oaks, CA (US)
Appl. No. 17/601,417
Filed by TENEOBIO, INC., Newark, CA (US)
PCT Filed Apr. 3, 2020, PCT No. PCT/US2020/026686
§ 371(c)(1), (2) Date Oct. 4, 2021,
PCT Pub. No. WO2020/206330, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/830,130, filed on Apr. 5, 2019.
Prior Publication US 2022/0195068 A1, Jun. 23, 2022
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/3069 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/60 (2013.01); C07K 2317/92 (2013.01)] 28 Claims
 
1. An antigen-binding region of an anti-PSMA heavy chain antibody, comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 11, and a CDR3 sequence of SEQ ID NO: 18.